Effect of BPC-157 on Symptoms in Patients with Interstitial Cystitis: A Pilot Study
This pilot study evaluated the safety and efficacy of BPC-157, a peptide not yet FDA-approved, in treating moderate to severe interstitial cystitis (IC) in patients unresponsive to standard pentosan polysulfate therapy. Twelve female participants aged 39 to 76 received a single 10 mg intravesical injection of BPC-157 around inflamed bladder
June 26, 2025
No Comments